Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06450210
PHASE1

Safety for Home Administration of Microdose Psilocybin Use

Sponsor: Johns Hopkins University

View on ClinicalTrials.gov

Summary

The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.

Key Details

Gender

All

Age Range

21 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-12-06

Completion Date

2027-07

Last Updated

2026-02-23

Healthy Volunteers

Yes

Interventions

DRUG

psilocybin trihydrate

Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).

DRUG

Placebo

Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.

Locations (1)

5510 Nathan Shock Drive

Baltimore, Maryland, United States